324 results on '"Viñals, Francesc"'
Search Results
2. New genetic drivers in hemorrhagic hereditary telangiectasia
3. Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
4. Glycosylation defects, offset by PEPCK-M, drive entosis in breast carcinoma cells
5. Pharmacology and preclinical validation of a novel anticancer compound targeting PEPCK-M
6. PEPCK-M recoups tumor cell anabolic potential in a PKC-ζ-dependent manner
7. Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis
8. Ovarian cancer relies on the PDGFRβ–fibronectin axis for tumorsphere formation and metastatic spread
9. PDGFR-induced autocrine SDF-1 signaling in cancer cells promotes metastasis in advanced skin carcinoma
10. Ovarian cancer relies on the PDGFRβ–fibronectin axis for tumorsphere formation and metastatic spread.
11. Data from A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination
12. Supplementary Figures 1-12 from A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination
13. Supplementary Figure 3 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
14. Supplementary Methods from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
15. Supplementary Figure 2 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
16. Supplementary Figure 4 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
17. Supplementary Figure 5 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
18. Data from Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors
19. Supplementary Figure 6 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
20. Supplementary fig 2 from Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent
21. Supplementary Data from FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma
22. Suplementary fig 3 from Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent
23. Supplementary fig 5 from Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent
24. Supplementary Figure 1 from Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer
25. Supplementary Table 1 from Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer
26. Supplementary Data from Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors
27. Supplementary figure 1 from Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent
28. Supplementary Figure 1 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
29. Supplementary data from Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent
30. Supplementary fig 4 from Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent
31. Supplementary Figure 1 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
32. Supplementary Figures 1 through 7, Supplementary Tables 1 and 3, and Supplementary Materials and Methods from Cancer Stem-like Cells Act via Distinct Signaling Pathways in Promoting Late Stages of Malignant Progression
33. Supplementary Figure 7 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
34. Supplementary Figure 5 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
35. Supplementary Table 2 from Cancer Stem-like Cells Act via Distinct Signaling Pathways in Promoting Late Stages of Malignant Progression
36. Supplementary Methods, Figure Legends 1-7 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
37. Data from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
38. Supplementary Figure 3 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
39. Supplementary Figure 4 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
40. Supplementary Figure 2 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
41. Supplementary Figure 6 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
42. Preclinical Activity of Metronomic Regimens with Alkylating Agents and Antimetabolites
43. Generation and Integrated Analysis of Advanced Patient‐Derived Orthoxenograft Models (PDOX) for the Rational Assessment of Targeted Therapies in Endometrial Cancer
44. Mitochondrial Phosphoenolpyruvate Carboxykinase (PEPCK-M) Is a Pro-survival, Endoplasmic Reticulum (ER) Stress Response Gene Involved in Tumor Cell Adaptation to Nutrient Availability
45. Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility
46. S
47. Glycosylation defects, offset by PEPCK-M, drive entosis in breast carcinoma cells
48. Rethinking growth factors: the case of BMP9 during vessel maturation
49. Filamin B Plays a Key Role in Vascular Endothelial Growth Factor-induced Endothelial Cell Motility through Its Interaction with Rac-1 and Vav-2
50. Correction: Corrigendum: A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.